Prevalence of <i>Helicobacter pylori</i> Antimicrobial Resistance Among Chilean Patients

Simple item page
dc.contributor.authorGonzalez-Hormazabal, Patricio
dc.contributor.authorArenas, Alex
dc.contributor.authorSerrano, Carolina
dc.contributor.authorPizarro, Margarita
dc.contributor.authorFuentes-Lopez, Eduardo
dc.contributor.authorArnold, Jorge
dc.contributor.authorBerger, Zoltan
dc.contributor.authorMusleh, Maher
dc.contributor.authorValladares, Hector
dc.contributor.authorLanzarini, Enrique
dc.contributor.authorJara, Lilian
dc.contributor.authorCastro, V. Gonzalo
dc.contributor.authorCamargo, M. Constanza
dc.contributor.authorRiquelme, Arnoldo
dc.date.accessioned2025-01-20T22:11:15Z
dc.date.available2025-01-20T22:11:15Z
dc.date.issued2021
dc.description.abstractBackground. Treatments for Helicobacter pylori (H. pylori) eradication include the use of antibiotics and a proton-pump inhibitor. Antibiotic resistance is a major concern for two drugs: levofloxacin and clarithromycin. The aim was to determine the prevalence of levofloxacin resistance (LevoR) and clarithromycin resistance (ClaR) in an urban population in Santiago, Chile.
dc.description.abstractMethods. Gastric mucosa biopsies were obtained for DNA isolation from 143 H. pylori-positive individuals aged 18-80 years. Direct sequencing of the quinolone-resistance determining region (QRDR) of the gyrA gene was used to determine LevoR. ClaR was determined using restriction-fragment length polymorphism or 5'exonuclease assay.
dc.description.abstractResults. The prevalences of LevoR and ClaR were 29 and 27%, respectively. LevoR was higher in women than in men (39 vs. 13%, p <0.001), while no sex difference was observed for ClaR (p= 0.123). The prevalence of LevoR increased with age (p-trend =0.004) but not for ClaR (p-trend=0.054). In sex-stratified analyses, both LevoR and ClaR increased with age only among women. Older women (>50 years) had a higher probability to carry LevoR strains as compared to men. The prevalence of dual LevoR and ClaR was 12.6%.
dc.description.abstractConclusions. The prevalence of ClaR and LevoR is high in Santiago, according to International guidelines that recommend avoiding schemes with antibiotic resistance >15%. Our findings provide evidence to re-evaluate current therapies and guide empirical first-and second-line eradication treatments in Chile. (C) 2021 Instituto Mexicano del Seguro Social (IMSS). Published by Elsevier Inc. All rights reserved.
dc.fuente.origenWOS
dc.identifier.doi10.1016/j.arcmed.2021.01.011
dc.identifier.eissn1873-5487
dc.identifier.issn0188-4409
dc.identifier.urihttps://doi.org/10.1016/j.arcmed.2021.01.011
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/94400
dc.identifier.wosidWOS:000683058800008
dc.issue.numero5
dc.language.isoen
dc.pagina.final534
dc.pagina.inicio529
dc.revistaArchives of medical research
dc.rightsacceso restringido
dc.subjectHelicobacter pylori
dc.subjectResistance
dc.subjectLevofloxacin
dc.subjectClarithromycin
dc.subjectAge
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titlePrevalence of <i>Helicobacter pylori</i> Antimicrobial Resistance Among Chilean Patients
dc.typeartículo
dc.volumen52
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas